BioSpace News Archive

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), today announced that Stefan Weber, CEO, will present at the 22nd Annual BIO CEO & Investor Conference in New York, NY on Tuesday, February 11, 2020 at 11:00 a.m. ET in the Odets room (4th floor) at the New York Marriott Marquis.

Data from digital inhalers reveals an increased use of rescue inhalers for asthma symptoms due to short-term exposure to ozone, even below the ozone level set by the EPA

AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company will provide clinical data updates for its investigational programs in Fabry disease and cystinosis, as well as present data from the first clinical use of its plato™ gene therapy platform, including an optimized vector, automated manufacturing system and personalized conditioning regimen.

Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced the dosing of the first patient in a phase 2 clinical trial of AKST4290, an orally administered CCR3 inhibitor, for treatment of Parkinson’s disease.

Osteoporosis is defined as a systemic skeletal disorder characterized by low bone mass, deterioration of bone tissue leading to enhanced bone fragility, and a consequent increase in fracture risk.

Vital Data Technology, LLC, a leading health IT company serving the payer landscape, today announced the appointment of Chuck Rolfsen as Chief Revenue Officer.

Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended December 31, 2019.

Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2019.

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following conferences during the months of February:

Baxter International Inc. (NYSE:BAX), a leading global medical products company, and Spectral Medical Inc. (TSX:EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced a distribution agreement for TORAYMYXIN™ PMX-20R (PMX), a hemoperfusion filter, and the Endotoxin Activity Assay™ (EAA), an on-market companion diagnostic tool that aids in the risk assessment of ICU patients for progression to severe sepsis